INTRODUCTION {#s1}
============

Acute pancreatitis (AP) is the rapid onset of inflammation of the pancreas in response to injury. Pancreatitis is one of the most common causes of gastrointestinal-related hospitalizations and a considerable healthcare burden ([@R1],[@R2]). Although most of the cases will resolve with time, a subset of patients will develop organ failure with mortality rates reaching 20% in patients with severe AP ([@R3]--[@R5]). Currently, there is no validated model to predict AP severity. Furthermore, current treatment is restricted to supportive care ([@R6],[@R7]).

The mechanisms underlying the development of AP and the progression to severe disease are unclear. Triggering events lead to an uncontrolled inflammatory response ([@R2]), and the intensity of inflammation is linked to disease severity ([@R8],[@R9]). After injury, innate immune cells, primarily neutrophils and macrophages, rapidly infiltrate the pancreas ([@R10],[@R11]), resulting in damaging levels of cytokines, termed a "cytokine storm," leading to tissue damage, organ failure, and impaired pancreas regeneration ([@R9],[@R12],[@R13]). However, although inhibition of major proinflammatory cytokines, such as tumor necrosis factor (TNF) and interleukin (IL) 6, has shown promise in preclinical models, it has not been translated to patient benefit ([@R9]).

Activin A, a member of the TGFβ superfamily, is a cytokine associated with the immune response ([@R14]--[@R16]) and plays a key role in various murine models of inflammatory disease, such as inflammatory bowel disease, asthma, viral infections, and obesity ([@R16]--[@R21]). We have previously shown that serum activin A levels in patients with AP positively correlate with disease severity and that inhibition of activin A in a murine model of severe AP drastically reduced the initiation of disease-related mortality ([@R22]).

In our previous assessment of serum activin A levels as a marker for AP disease severity ([@R22]), we did not consider the impact of body mass index (BMI), a known risk factor of patients developing severe disease ([@R23],[@R24]). Serum activin A levels are increased in subjects with BMI more than 30 ([@R25]), leading to the concern that elevated serum activin A levels in severe AP might reflect BMI status. In this report, using the same clinical cohort, we examined whether elevated serum activin A levels in patients with AP are independent of BMI. Using the murine AP model of IL12/IL18 injection in *ob*/*ob* mice, we previously reported that blocking activin A at the initiation of AP was effective in reducing the severity of AP ([@R22]). In this study, we verify that observation using the well-established cerulein injection murine model. We provide additional studies to address the therapeutic potential of blocking activin A once AP is established. In addition, we examine the role of activin A on the immune response during the development of AP.

METHODS {#s2}
=======

Cell lines, culture, and stimulants {#s2-1}
-----------------------------------

Human pancreas stellate cells (hPSC) and human ductal epithelial cells (HPDE) were a generous gift from Dr Paul Grippo (University of Illinois at Chicago \[UIC\]). HPSC cells were originally developed by Dr Rosa Hwang (The University of Texas MD Anderson Cancer Center) ([@R26]). RAW264.7 cells were a generous gift from Dr Jun Sun (UIC). Cells were validated with CellCheck 9 Plus and tested for mycoplasma (IDEXX). HPSCs were maintained in DMEM supplemented with antibiotics and 10% fetal bovine serum (Invitrogen). HPDE cells were maintained in keratinocyte media supplemented with epidermal growth factor 1--53 and bovine pituitary extract (Gibco, Waltham, MA). RAW264.7 cells were maintained in Roswell Park Memorial Institution media (Gibco) supplemented with 10% fetal bovine serum. Cells were plated with serum-free media 24 hours before any treatments. To simulate an inflammatory environment, cells were stimulated with TNF (1--100 ng/mL) or Lipopolysaccaride (LPS) (0.1--10 μg/mL) (Cell Signaling Technology). RAW264.7 cells were treated with 25 ng/mL of activin A peptide (R&D Systems, Minneapolis, MN). Phosphate-buffered saline was used as a control treatment.

Murine models of AP {#s2-2}
-------------------

Female C57BL mice (Charles River Laboratories), aged 9--10 weeks, received 12 hourly intraperitoneal injections of cerulein at 50 μg/kg (Sigma-Aldrich, Burlington, MA). Control mice received equal volume of phosphate-buffered saline injections. To inhibit activin A, mice received a single injection of activin A-specific mouse monoclonal neutralizing antibody (AF388; R&D Systems) at 2 mg/kg either 30 minutes before the start of cerulein injections or at 7 hours of cerulein injections. A monoclonal mouse IgG~1~ isotype (R&D Systems) injection of equal volume and concentration was given as a control treatment. All animal protocols and experiments were approved by the Animal Care and Use Committee of UIC and performed in accordance with their guidelines and regulations.

Murine sample preparation and assessment {#s2-3}
----------------------------------------

Blood was mixed with heparin and centrifuged to isolate plasma. Pancreatic tissue was fixed in 10% formalin, paraffin embedded, and sectioned as previously described ([@R22]). Tissue sections were stained with hematoxylin and eosin (H&E) and scored for edema, necrosis, disease severity, and neutrophil infiltration as previously described ([@R22]). Immunohistochemical staining of CD68 (ab955; Abcam), TGFβ1 (ab125287; Abcam), and inhibin βA (subunit of activin A) (AI006; Ansh Labs, Webster, TX) was performed as previously described ([@R27]). In all cases, slides were blindly scored by 2 independent investigators and received scores of 0 (no staining), 1 (minimal staining), 2 (moderate staining), or 3 (high staining).

Protein and mRNA detection {#s2-4}
--------------------------

### ELISA {#s2-4-1}

Activin A from murine plasma and cell media supernatant was measured with the activin A Quantikine ELISA kit (R&D Systems, Minneapolis, MN) following the manufacturer\'s instructions. Plasma samples and hPSC supernatants were diluted 1:2 and 1:3, respectively. α-Amylase was measured using a kit from Teco Diagnostics (Anaheim, CA) according to the manufacturer's instructions. Samples were assayed in duplicate.

### Immunoblotting and antibodies {#s2-4-2}

Immunoblotting was performed as previously described ([@R28]) with the following antibodies: mouse monoclonal to inhibin βA (AI006; Ansh), mouse monoclonal to α-tubulin (3873; Cell Signaling Technology), and rabbit polyclonal to β-actin (4967; Cell Signaling Technology).

### Quantitative real-time polymerase chain reaction {#s2-4-3}

Total RNA was isolated from study cells with the RNeasy Plus Kit (Qiagen, Waltham, MA) following manufacturer\'s instructions. Complementary DNA was synthesized with the SuperScript Vilo cDNA Synthesis Kit (Invitrogen, Waltham, MA). TaqMan gene expression assays for *INHBA*, *TNF*, and *IL1B* were used with TaqMan Fast Advanced Master Mix according to manufacturer\'s instructions (Applied Biosystems, Waltham, MA). Quantitative real-time polymerase chain reaction was performed on a ViiaA7 instrument (Applied Biosystems). The results were normalized to 2 independent control genes (*RPL13A* and *B2M* \[human\] or *MRPL19* \[mouse\]) using GeNorm software ([@R29]).

Human cohort with pancreatitis {#s2-5}
------------------------------

A detailed description of this cohort has been previously published ([@R22]). Subjects were recruited at the University of Pittsburgh Medical Center, and all protocols were approved by the Institutional Review Board of University of Pittsburgh. An informed consent was obtained for all participants. Deidentified patient serum samples (from 30 control subjects and from 10 patients with mild, 10 with moderate, and 10 with severe AP according to revised Atlanta criteria ([@R3])) were analyzed at UIC, as previously described ([@R22]).

Statistical analysis {#s2-6}
--------------------

Data are presented as mean ± SD. All statistical tests were 2 sided, and *P* values \<0.05 were considered statistically significant. In 1- or 2-sample cases, a paired or unpaired *t* test was performed as appropriate to determine significant differences between treatments and conditions. For continuous variables, 1-way analysis of variance or nonparametric Kruskal--Wallis tests were conducted as appropriate; for categorical variables, χ^2^ or Fisher exact tests were conducted as appropriate. The parametric or nonparametric *P* values were reported based on the normality test of distribution. Multivariate analyses were conducted using generalized estimating equations to model the disease severity by including activin A and BMI as predictors controlled by age and sex. Ordered logistic regression was performed to analyze disease severity by including disease severity as a response variable and 4 BMI/activin A groups and time as predictors. To test independence of activin A and BMI as predictors of disease severity, multiple collinearity analysis was conducted for disease severity, activin A, and BMI along with other covariates. Statistical analyses were conducted using SAS version 9.4 (SAS Institute) or Prism (GraphPad Software).

RESULTS {#s3}
=======

Serum activin A level and BMI are independent prognostic tools for patients with AP {#s3-1}
-----------------------------------------------------------------------------------

It is difficult to predict which patients with AP will progress to severe disease. Previously, our group demonstrated a positive correlation between serum activin A levels of patients and disease severity ([@R22]), but we did not consider the impact of BMI in this analysis to determine whether elevated serum activin A levels are dependent or independent of BMI. Using that same cohort of patients ([@R22]), we reanalyzed these data using subject BMI as a variable. As described previously ([@R22]), blood samples from each patient were collected at admission, 24 hours postadmission, and between 48 and 72 hours postadmission.

The univariate generalized estimating equations modeling results show that both activin A (estimated β = 1.43, *P* = 0.0002) and BMI (estimated β = 0.07, *P* = 0.0102) positively predict the severe of disease individually with the different measurements of activin A having no effect on this prediction. The logistic regression also showed that activin A and BMI predict severe disease individually with odds ratios of comparing moderate or severe vs control or mild are 53.75 (95% confidence interval: 8.07--357.79), *P* \< 0.001, for activin A, and 1.13 (95% confidence interval: 1.06--1.21), *P* \< 0.001, for BMI, respectively. These results suggest that activin A and BMI were independent predictors of disease severity. The multiple collinearity test showed the nonexistence of collinearities among activin A, BMI, and other covariates (e.g., age and sex), which further indicates that activin A and BMI independently predict the disease severity.

High BMI is a known risk factor associated with severe AP ([@R23],[@R24]), confirmed in a murine model of AP where lean mice expressed mild disease whereas obese mice exhibited sever disease ([@R30]). The BMI value of 30 has been widely accepted to indicate obese subjects ([@R31]), and therefore, we have used that value as our cutoff to indicate high BMI. The predictive value of BMI for severe AP is limited. As shown in Figure [1](#F1){ref-type="fig"}, there are patients with both mild and moderate AP with a BMI \> 30 and patients with severe AP with a BMI ≤30. Of clinical relevance, there is no predictive measure for patients with low BMI who may progress to severe AP. Thus, we examined the serum activin A levels in the subgroup of patients with low BMI, defined as patients with BMI ≤30 (Figure [1](#F1){ref-type="fig"}b). In this group, activin A strongly predicted disease severity (*P* \< 0.01). This suggests that patient's BMI and serum activin A levels can be used independently to predict the probability of patients developing severe AP and identify those that require more focused care.

![Serum activin A level of patient is independent of BMI as a prognostic tool for AP disease severity. (**a**) ELISA of serum activin A levels (y axis) plotted against the patient BMI (x axis) distributed by disease severity group (control = inverted triangle; mild AP = square; moderate AP = triangle; severe AP = circle) n = 10 for each group with activin A estimated at admission and 24 hr and 48--72 hr after admission for each patient. (**b**) Serum activin A levels in those subjects with a BMI ≤30. GEE multivariate analysis confirmed that serum activin A level is predictive of disease severity for patients with low BMI (*P* \< 0.0001). AP, acute pancreatitis; BMI, body mass index; GEE, generalized estimating equation.](ct9-11-e00152-g001){#F1}

Activin A inhibition reduces inflammation and disease severity in AP murine model {#s3-2}
---------------------------------------------------------------------------------

In addition to being a powerful prognostic marker, previous data from our laboratory suggest that activin A has a mechanistic role in AP ([@R22]). To verify the requirement of activin A in the development of AP, we used a cerulein-induced murine model of AP. Thirty minutes before the 12 hourly cerulein injections (50 μg/kg), mice received either an activin A-specific neutralizing antibody (2 ng/kg) or an equal amount of immunoglobulin G (IgG) isotype control antibody. Mice were killed 24 hours after the first cerulein injection (Figure [2](#F2){ref-type="fig"}a). Amylase activity was measured to confirm the development of pancreatitis (see Figure 1A, Supplementary Digital Content 1, <http://links.lww.com/CTG/A284>), and activin A plasma levels were assessed by an activin A-specific ELISA. Treatment with the neutralizing antibody successfully reduced activin A to undetectable levels (see Figure 1B, Supplementary Digital Content 1, <http://links.lww.com/CTG/A284>).

![Inhibition of activin A in cerulein-induced AP murine model reduces disease severity and inflammation. (**a**) Schematic of treatment and cerulein injection schedule. Mice were pretreated with activin A-specific neutralizing antibody (Anti-Act) or IgG control 30 minutes before the start of cerulein injections. Mice were given 12 hourly injections of 50 μg/kg cerulein or equal volume PBS. Blood and tissue were collected 24 hr after the start of cerulein injections. (**b**) Stained sections of pancreatic tissue from mice with cerulein-induced AP. Top row, H&E staining; middle row, IHC staining of CD68; and bottom row, IHC staining of TGFβ. Representative images were taken at ×40 total magnification. (c) Quantification of pancreatic tissue staining. n = 5--10 mice per group. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. AP, acute pancreatitis; IHC, immunohistochemical; PBS, phosphate-buffered saline.](ct9-11-e00152-g002){#F2}

H&E staining of mouse pancreatic tissue revealed significant differences in disease severity with activin A inhibition. Mice treated with the neutralizing antibody had less edema and necrosis compared with IgG control-treated mice (Figure [2](#F2){ref-type="fig"}b,C). Moreover, mice with activin A inhibition also had less inflammation. Neutrophil infiltration was significantly reduced, as was CD68 macrophage infiltration (Figure [2](#F2){ref-type="fig"}b,c). Overall, these data suggest that activin A is necessary for the full development of cerulein-induced pancreatitis and likely plays a role in immune cell infiltration of the pancreas.

TGFβ1 ligand, a relative of activin A ligand, increased in the pancreas with disease as expected ([@R32]), but did not change significantly with activin inhibition (Figure [2](#F2){ref-type="fig"}b,c), indicating the influence of activin A specifically on AP disease development. The anti-activin antibody was also administered at 7 hours of cerulein injection as an AP treatment (Figure [3](#F3){ref-type="fig"}a). Mice were collected at 24 hours to assess parameters of AP and at 7 days to assess regeneration. At 24 hours, the anti-activin treatment significantly reduced pancreatic edema (Figure [3](#F3){ref-type="fig"}b,c), necrosis (Figure [3](#F3){ref-type="fig"}b,d), pancreas:body weight ratio (Figure [3](#F3){ref-type="fig"}e), neutrophil infiltration (Figure [3](#F3){ref-type="fig"}b,f), and disease severity score (Figure [3](#F3){ref-type="fig"}g). The role of activin in tissue regeneration at the resolution of pancreatitis is controversial and requires additional studies. Reduction of pancreatic regeneration in patients with AP would be concerning. We analyzed the pancreata collected 7 days after initiation of AP and compared mice treated with a control IgG to those treated with anti-activin (Figure [3](#F3){ref-type="fig"}). By all the criteria measured, the anti-activin--treated pancreata returned to control values and appeared to have normal architecture on H&E staining. The IgG-treated mice had values above control for 4 of the measured assays indicating some residual disease.

![Inhibition of activin A treatment of cerulein-induced AP decreases disease severity but does not reduce pancreas regeneration. (**a**) Schematic of treatment and cerulein injection schedule. Mice (n = 3--5) were given 12 hourly injections of 50 μg/kg cerulein or equal volume PBS. At 7 hr of cerulein injection, mice were treated with activin A-specific neutralizing antibody (Anti-Act) or IgG control. Blood and tissue were collected 24 hr after the start of cerulein injections and at 7 d. (**b**) Hematoxylin/eosin stained pancreatic sections at ×10 magnification. (**c**) Edema score at 24 hr and 7 d of cerulein injection with and without Anti-Act. (**d**) Percentage of pancreatic necrosis, (**e**) pancreas:body weight ratio, (**f**) neutrophil infiltration score, and (**g**) AP severity score. \*\**P* \< 0.01, \*\*\**P* \< 0.001. AP, acute pancreatitis; PBS, phosphate-buffered saline.](ct9-11-e00152-g003){#F3}

Activin A is produced and released by pancreas cells but not macrophages {#s3-3}
------------------------------------------------------------------------

To delineate the relationship between activin A and an immune response during AP, we treated pancreatic hPSC and HPDE cell lines with TNF to simulate an inflammatory environment as seen in AP. Levels of *INHBA* mRNA, which encodes the βA subunit of activin A, increased significantly, indicating increased transcription of activin A precursors (Figure [4](#F4){ref-type="fig"}a). Accordingly, protein levels of the profrom βA subunit of activin A also increased in both cell lines (Figure [4](#F4){ref-type="fig"}b,c). βA subunits are processed and dimerize outside of the cell; thus, fully formed activin A cannot be detected by immunoblots of cell lysate ([@R33]).

![Activin A is produced and released by pancreatic cell lines but not by macrophage cell lines. (**a**) qRT-PCR results of *INHBA* mRNA levels in hPSC and HPDE cells after 24-hr treatment with 10 ng/mL TNF. (**b**) Representative immunoblots of the βA subunit proform of activin A in hPSC and HPDE cells after 24-hr treatment with 10 ng/mL TNF. Loading control is α-tubulin for hPSC cells and β-actin for HPDE cells. (**c**) Densitometry quantification of immunoblots of at least 3 independent experiments. (**d**) ELISA of activin A in cell culture media of hPSC and HPDE cells after treatment with increasing concentrations of TNF or LPS for 24 hr. (**f**) ELISA of activin A in cell culture media of RAW264.7 cells treated with 10 ng/mL TNF or 10 μg/mL LPS for 24 hr. Activin A in the media was undetectable. (**e**) *INHBA* mRNA level in RAW264.7 cells after activation with 10 ng/mL TNF. \**P* \< 0.05; \*\**P* \< 0.01. HPDE, human ductal epithelial cells; hPSC, human pancreas stellate cells; qRT-PCR, quantitative real-time polymerase chain reaction.](ct9-11-e00152-g004){#F4}

Release of activin A from hPSC and HPDE cells was measured by activin A-specific ELISA of cell culture supernatants. Treatment with inducers of inflammatory responses, either TNF or LPS, caused an increase in activin A release in a dose-dependent manner (Figure [4](#F4){ref-type="fig"}d). Conversely, a macrophage cell line, RAW264.7, did not release detectable amounts of activin A in response to stimulation with TNF or LPS (Figure [4](#F4){ref-type="fig"}e), nor did TNF treatment induce an increase in *INHBA* mRNA production in these cells (Figure [4](#F4){ref-type="fig"}f). This suggests that activin A might come from the pancreas cells during AP.

Activin A activates macrophage cell lines {#s3-4}
-----------------------------------------

Despite not releasing activin A, macrophage cells were responsive to activin A treatment. RAW264.7 cells were treated with activin A peptide for 24 hours. Levels of *TNF* and *IL1B* mRNA more than doubled with activin A treatment (Figure [5](#F5){ref-type="fig"}a,B), suggesting that macrophages can become activated in response to activin A. Taken together, our data suggest a model of AP where, after injury, stimulated pancreatic cells produce and release activin A that mediates an immune response, contributing to the inflammatory storm of AP that can lead to severe disease progression.

![Activin A activates RAW264.7 macrophages. qRT-PCR results of *TNF* and *IL1B* mRNA expression in RAW264.7 macrophages after 24-hour treatment with 25 ng/mL activin A. \**P* \< 0.05. qRT-PCR, quantitative real-time polymerase chain reaction.](ct9-11-e00152-g005){#F5}

DISCUSSION {#s4}
==========

AP remains a critical public health challenge partly because of the inability to accurately predict patients who will develop severe disease, which can be lethal, and the lack of curative treatment options ([@R3]--[@R7]). In this study, we reexamined our clinical data and determined that elevated serum activin is independent of an elevated BMI as a marker of severe AP. This suggests serum activin A levels can be useful to predict the development of severe AP in patients with BMI ≤30. The data obtained from the cohort used in this study strongly support the need for a larger prospective study of activin A as a prognostic marker in AP. AP is a complex disease, and the limited sample size in this study prevented subgroup analysis.

In this study, we validated the necessity of activin A for the full development of AP in the cerulein model of pancreatitis. Mice pretreated with activin A-specific neutralizing antibody had significantly less severe disease than control mice. Thus, an immediate clinical application of activin A inhibition could be considered as a prophylactic before endoscopic retrograde cholangiopancreatography to prevent procedure-induced pancreatitis, which occurs in 3%--5% of cases ([@R34]). Additional studies will help to identify the appropriate timing of activin inhibition to inform clinical application.

In addition, we found that treatment with the anti-activin antibody after the initiation of cerulein-induced AP was effective in reducing disease. Clinical inhibition of activin A is feasible, because the safety has been demonstrated in patients suffering from chemotherapy-induced anemia and ovarian cancer ([@R35],[@R36]). Thus, with appropriate additional preclinical studies to examine timing of activin A peak levels, activin A inhibition could rapidly translate to clinical application. We have initiated a prospective clinical study to collect those data.

We further observed that the anti-activin treatment does not impair longer-term pancreas regeneration and might have assisted the regeneration process. One possibility is that anti-activin treatment prevented much of the cerulein-induced pancreatic damage and, therefore, the pancreata appear more normal at 7 days. It is also possible that inhibiting activin promotes repair of the pancreas. This would be useful in cases where patients present at the emergency department when their AP is fully developed and the therapeutic window to prevent an inflammatory response might be closed. However, if activin inhibition also promotes regeneration in addition to ameliorating the inflammatory response, there may be a broader clinical application for anti-activin therapy.

Using murine models of AP, we identified a link between activin A and innate immune cell infiltration of the pancreas. This closely correlated to disease severity. Our *in vitro* studies suggest that activin A is released by pancreatic cells and activates macrophages. This may be a key initiating element of the inflammatory response during AP that activin A inhibition could interrupt.

Dysregulation of cells of exocrine pancreas, primarily acinar and ductal epithelial cells, initiate pancreatitis, which, in turn, promotes an inflammatory response ([@R37]). Pancreatic stellate cells are understudied in AP, but it is known they can become activated in an inflammatory environment, such that occurs during AP. Stellate cells respond, in turn, by promoting fibrosis that can lead to chronic pancreatitis and the release of additional cytokines that prolong the immune response ([@R38]). In this report, we identified activin A as a potential signaling molecule released by pancreatic stellate and epithelial cells, which could act as a key factor in progressing the inflammatory response.

In conclusion, through *in vitro* models, murine models, and clinical data, we have demonstrated a key role of activin A in AP initiation and progression. Serum activin A level of patients acts a useful tool alone or in combination with patients' BMI to help predict patients in need for more focused care. Moreover, inhibition of activin A in patients is safe and promises to impede the deleterious inflammatory response that occurs during AP, which may ultimately improve patient outcomes.
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